HRS-1893 (also known as BHB-1893) is a selective, small-molecule, cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By modulating cardiac contractility, HRS-1893 ...

The cardiovascular safety of an interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there was no benefit to the ...

"ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose" was originally created and published by Pharmaceutical ...

CHICAGO, IL—An unconventional approach to combat left ventricular remodeling following myocardial infarction appears to improve heart function and patient symptoms, although investigators caution it’s ...

Is your heart functioning properly? There is a test which can measure this, which is often recommended by medical ...

Bayer advances AB-1002 after AskBio completes mid-stage study enrollment, as its Pharma strategy and pipeline milestones drive long-term growth outlook.

Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...

Trial shows fewer HF hospitalizations in HFpEF ...

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...

The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...